ARQT Arcutis Biotherapeutics, Inc.

Healthcare [ 3/11 ] | Biotechnology [ 38/157 ]

US | NASDAQ | Stock

Price: $11

Increased by +0.01%
Dollar Volume: 14.35 M
ADR%: 6.72
Earnings Report Date (estimate): May 3, 23 (N/A)

Market Cap.: 671.91 M
Shares Float: 50.42 M
Shares Outstanding: 61.08 M

Beta: 0.52
Price / Earnings: -1.96
BPR: 5.79

20D Range: 10.05 15.47
50D Range: 10.05 17.57
200D Range: 10.05 27.40

Quarterly Earnings
Annual Earnings

Reported Date	EPSChange YoY	EstimateSurprise
Feb 28, 23	-1.18 Increased by +16.90%	-1.42 Increased by +11.90%
Nov 8, 22	-1.89 Decreased by -33.10%	-1.67 Decreased by -7.89%
Aug 4, 22	-1.31 Decreased by -14.91%	-1.41 Increased by +5.03%
May 5, 22	-1.27 Decreased by -51.19%	-1.50 Increased by +10.22%
Feb 22, 22	-1.42 Decreased by -86.84%	-1.49 Increased by +3.15%
Feb 16, 22	-1.42 Decreased by -79.75%	-1.49 Increased by +3.15%
Nov 4, 21	-1.14 Decreased by -12.87%	-1.15 Increased by +0.76%
Aug 5, 21	-0.84 Increased by +10.64%	-0.90 Increased by +7.41%

Quarterly Financials
Annual Financials

Fiscal ending date	RevenueChange YoY	IncomeChange YoY	ProfitChange YoY
Sep 30, 22	725.00 K Increased by +N/A%	-107.71 M Decreased by -89.03%	Decreased by -14.86 K% Decreased by N/A%
Jun 30, 22	0.00 Decreased by N/A%	-67.41 M Decreased by -60.46%	Decreased by N/A% Decreased by N/A%
Mar 31, 22	0.00 Decreased by N/A%	-64.32 M Decreased by -78.47%	Decreased by N/A% Decreased by N/A%
Dec 31, 21	0.00 Decreased by N/A%	-71.33 M Decreased by -109.48%	Decreased by N/A% Decreased by N/A%
Sep 30, 21	0.00 Decreased by N/A%	-56.98 M Decreased by -49.15%	Decreased by N/A% Decreased by N/A%
Jun 30, 21	0.00 Decreased by N/A%	-42.01 M Decreased by -18.63%	Decreased by N/A% Decreased by N/A%
Mar 31, 21	0.00 Decreased by N/A%	-36.04 M Decreased by -28.66%	Decreased by N/A% Decreased by N/A%
Dec 31, 20	0.00 Decreased by N/A%	-34.05 M Decreased by -170.92%	Decreased by N/A% Decreased by N/A%

Top 20 ETF Stock Exposure
Top 20 Institutional Holders
Top 20 Mutual Fund Holders

Rank	ETF	Shares	Market Value	Weight % in ETF

DAILY

WEEKLY

MONTHLY

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.